Fabio Cataldi has served as Abivax's Chief Medical Officer since July 2024. He has over 20 years of experience in the development and commercialization of innovative therapies, with deep clinical, medical and scientific expertise in immunology and gastroenterology, having served in senior research and development roles at Arena Pharmaceuticals, AbbVie, Shire, Pfizer, Biogen and Novartis. Most recently he was Chief Medical Officer at Landos Biopharma until its sale to AbbVie. At Abivax he oversees clinical operations, clinical development, pharmacovigilance and medical affairs. He holds an M.D. in Medicine and Surgery from the Seconda Università degli Studi di Napoli.